Settlement announced for most Depo-Provera meningioma claims

Plaintiffs' leadership in MDL No. 3140 (N.D. Fla.) announced a settlement with Pfizer and Pharmacia covering most claims in the MDL and in New York state court. The suits allege that the injectable contraceptive is linked to meningioma. Court orders later reported that a Master Settlement Agreement was signed in July and that about 80% of MDL plaintiffs are expected to be eligible; the dollar terms have not been disclosed.

Why it matters. Under Case Management Order No. 14, settlement registration runs through November 30, 2026, and the court set an initial bellwether trial for December 7, 2026, subject to its rulings on preemption and expert evidence.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment. Depo-Provera remains approved by the U.S. Food and Drug Administration.

Products named here remain subject to FDA approval, clearance or recall status, which can change; check the FDA databases for current status.